T-Therapeutics, a Cambridge-based biotechnology company specializing in the development of TCR therapeutics, has successfully raised $48M in Series A funding. The funding round was led by prominent investors such as Sofinnova Partners, F-Prime Capital, Digitalis Ventures, and Cambridge Innovation Capital. Sanofi Ventures and the University of Cambridge Venture Fund also participated in the funding round. As part of the financing, Graziano Seghezzi from Sofinnova Partners, Nihal Sinha from F-Prime, Samuel Bjork from Digitalis, and Robert Tansley from CIC will join the Company's Board of Directors.
The company plans to utilize the funds raised to advance its research and development efforts in discovering novel T cell receptor (TCR) therapeutics.
Primarily focused on cancer indications and inflammatory disorders, T-Therapeutics aims to harness the power of T cell biology to create safe and effective treatments for these conditions. The company, which was spun off from the University of Cambridge, is led by CEO Allan Bradley and boasts a team of experts in various fields, including mouse genome engineering, biopharmaceutical drug development, single cell genomics, machine-learning, and structural biology. This diverse expertise allows for a culture of creativity and collaboration within the company.
T-Therapeutics is currently developing TCR-based therapeutics using its proprietary OpTiMus® platform, which is based on a fully humanized TCR mouse. This platform provides an abundant source of antigen-specific human TCRs, enabling the creation of "optimal" TCR therapeutics that target multiple classes of diseases. With its innovative approach and strong financial backing, T-Therapeutics is well-positioned to make significant advancements in the development of TCR therapeutics and potentially revolutionize the treatment landscape for cancer and autoimmune diseases.
|Investor||Cambridge Innovation Capital|
Cambridge Innovation Capital